HomeBUSINESS
BUSINESS

Bristol-Myers Looks to Crack into Genotype 1 Hep C Market as Ximency Clears Resistance Mutation Hurdle
(Feb.15.2017)

Bristol-Myers Squibb is to soon roll out its new hepatitis C drug Ximency (daclatasvir + asunaprevir + beclabuvir) in Japan, aiming to regain its lost ground in the genotype 1 market, where it once claimed the lead with the launch of the country’s first interferon (IFN)-free treatment in 2014 ...
(LOG IN FOR FULL STORY)

News Calendar